⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 7, 2024Cancer Research and TreatmentOpen Access

Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma

Se Jin Choi Sung Won Chung Jonggi Choi Kang Mo Kim Hyung‐Don Kim Changhoon Yoo Baek‐Yeol Ryoo Seung Soo Lee Won‐Mook Choi Sang Hyun Choi

View Full Paper

Ask AI

Bookmark

Share

Abstract

This study aimed to identify clinical and radiologic characteristics that could predict response to atezolizumab-bevacizumab combination therapy in patients with advanced hepatocellular carcinoma (HCC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Choi et al. (2024) studied this question.

synapsesocial.com/papers/68e6b2a9b6db6435876344cf https://doi.org/10.4143/crt.2024.283

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Disease complexity and nodule-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma2025
2Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma2024 · 9 citations
3Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma2024 · 10 citations
4Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRICohort Study · 2026 · 1 citations
5Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinomaCohort Study · 2026